Suzanne Delbanco, PhD, MPH, of Catalyst for Payment Reform, and Patricia Salber, MD, MBA, of The Doctor Weighs In, discuss payment reform in the healthcare industry, including quality measurements and accountable care organizations.
The idea that the fee-for-service payment system in the United States has driven up utilization and costs in American healthcare has been common knowledge, which has led to the payment reform movement. In an attempt to correct for fee-for-service, the system layered different incentives on top of the fee-for-service payment method, explained Suzanne Delbanco, PhD, MPH executive director of Catalyst for Payment Reform, but more recently there has been shared savings arrangements.
During the latest Managed Care Cast, Delbanco and Patricia Salber, MD, MBA, of The Doctor Weighs In, discuss the latest in payment reform, avoiding perverse incentives, quality measurement, and more. In addition, they discuss accountable care organizations (ACOs) and what employers concerns regarding ACOs are and what they want out of ACOs that provide care for their workers.
Listen below or through one of these podcast services:
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
Specialty Drug Costs Drive Medicare Part D Dermatology Expenditures
July 22nd 2025The rapidly increasing prescriptions for expensive specialty medications, rather than their price growth, are the primary driver of escalating dermatology Medicare Part D expenditures, necessitating policies that balance innovation, access, and affordability.
Read More